Drug Development Programs Planned and Managed by Dr M J VandenBurg

Phase Ila

Go/No-go studies for:

A potassium channel activator
Calcium sensitiser
Insulin sensitiser
Anti-anginal
Anti-rheumatic disease modifier
Obsessive compulsive disorder
Anti-depressant
Anti-asthmatic
H2 antagonist
Many anti infectives
Drugs for hypertension
Heart failure
Angina and
Arrhythmias
Impotence

NSAID's Oral inotropes for CHF Anti nausea drugs Drugs for pain Peripheral vascular disease Homeopathic for flu Irritable Bowel Syndrome Alcohol abuse

Phase III programs for:

Three converting enzyme inhibitors H2 antagonist Many anti-infectives Potassium channel activator Non-steroidial anti-inflammatory drugs Vaccines for Hepatitis B Beta-blocker Anti-cancer agents Aids therapy Alcohol Addiction Parkinson's therapy Wound dressings Raised IOP

Phase IV programs:

Anti hypertensives
Antibiotics
H2 antagonist
Non-steroidial anti-inflammatory drugs
Anti-anginal
Anti-Bleeding Compounds.
Diuretic

Analysis, Study Reports, Safety and Efficacy Summaries, IND safety updates, NDA Filings and European Clinical Expert Report for:

Anti-arrhythmic Hypnotic Anti-epileptic Anti-Infective

Complete European submissions for:

Anti-hypertensives
Anaesthetics
Drugs for heart failure,
Angina
Anti-cancer agents
Anti-anaemic products
Drugs for bladder outflow
Anti-platelet agents
Antihistamines

Safety reports for many drugs relating to:

Cardiac, Hepatic, Renal and Photo Toxic Safety Issues as well as safety in stomach and colon

Only the major programs have been listed, single studies and consultancy projects have been carried out in almost all therapeutic areas as well as some niche areas such as:

- Cachexia in Aids
- Gene Therapy
- Autologous Transplantation and transfusion
- Blood substitutes
- Wound Growth Modifiers
- Anti oxidant in cardio vascular disease
- Alzheimer's
- Hepatitis A and B
- Anti-fungal
- Syjrogens Syndrome
- Anti-thrombotics